Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05816122 · ClinicalTrials.gov registry record · NA

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect

A NA study of Multiple Sclerosis, sponsored by Ad scientiam.

Active
Registry status
NA
Development phase
336
Enrollment target
20
Study locations

NCT05816122 is a NA study of Multiple Sclerosis that is active but no longer recruiting, run by Ad scientiam. The registered enrollment target is 336 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05816122, a NA study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Ad scientiam.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
336 participants
Enrollment target
20
Study locations

Study Summary

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients. Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL). Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression. The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France

Conditions Studied

Multiple Sclerosis

Interventions

  • DEVICE MSCopilot® Detect mobile application

Study Locations (20)

Other

  • Galina Vorobeychik - Burnaby
  • Mark Freedman - Ottawa
  • St. Michael's Hospital - Toronto
  • Robert Carruthers - Vancouver
  • University Hospital of Southern Denmark - Esbjerg
  • Finn Sellebjerg - Glostrup Municipality
  • Sivagini Prakash - Viborg
  • Hôpital Roger Salengro - Lille
  • Cécile Donzé - Lomme
  • Adil Maarouf - Marseille

California

  • Jennifer Graves - San Diego

Georgia

  • Joash Lazarus Sr. - Atlanta

Illinois

  • Daniel Wynn - Northbrook

Indiana

  • Craig E. Herrman - Indianapolis

Louisiana

  • Jennifer Feng - New Orleans

Missouri

  • Robert Naismith - St Louis

Ohio

  • Aaron Boster - Columbus

Trial Details

FieldValue
Enrollment Target 336 participants
Start Date 2023-09-22
Est. Completion 2027-05-31
Phase NA

Sponsor

Ad scientiam

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05816122

The ClinicalTrials.gov registry entry for NCT05816122 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (42% lower). The listed sponsor is Ad scientiam, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which MSCopilot® Detect mobile application is the first listed.

NCT05816122 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT05816122 about?

NCT05816122 is a clinical study titled "MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect". The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Wor...

What is the current status of trial NCT05816122?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 336 participants. The study started on 2023-09-22. Estimated completion is 2027-05-31.

What conditions does trial NCT05816122 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT05816122?

The interventions under investigation include: MSCopilot® Detect mobile application (DEVICE).

Who is sponsoring clinical trial NCT05816122?

This trial is sponsored by Ad scientiam, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05816122 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.